YTHDF1 and metabolic dysfunction-associated steatotic liver disease: Modulation of the Mettl3–m6A–YTHDF1 axis has the potential to improve mitochondrial function, alleviate MASLD symptoms, and decrease the likelihood of disease progression [115].